{
    "id": "6515924b-2014-4d8f-b704-f2092f2f5332",
    "indications": "zafirlukast indicated prophylaxis chronic treatment asthma adults children 5 years age older .",
    "contraindications": "food reduce bioavailability zafirlukast , zafirlukast taken least 1 hour 2 hours meals . adults children 12 years age older recommended dose zafirlukast adults children 12 years older 20 mg twice daily . pediatric patients 5 11 years age recommended dose zafirlukast children 5 11 years age 10 mg twice daily . elderly patients based cross-study comparisons , clearance zafirlukast reduced elderly patients ( 65 years age older ) , cmax auc approximately twice younger adults . trials , dose 20 mg twice daily associated increase overall incidence events withdrawals events elderly patients . patients hepatic impairment zafirlukast contraindicated patients hepatic impairment including hepatic cirrhosis ( ) . clearance zafirlukast reduced patients stable alcoholic cirrhosis cmax auc approximately 50 60 % greater normal adults . zafirlukast evaluated patients hepatitis long-term patients cirrhosis . patients renal impairment adjustment required patients renal impairment .",
    "warningsAndPrecautions": "zafirlukast 20 mg tablets - white , round , biconvex , film-coated tablets debossed `` p `` one side `` 20 `` . ndc : 72162-2362-6 : 60 tablets bottle store controlled room temperature , 20 25°c ( 68 77°f ) [ usp ] . protect light moisture . dispense original air-tight container . repackaged/relabeled : bryant ranch prepack , inc.burbank , ca 91504",
    "adverseReactions": "zafirlukast contraindicated patients hypersensitive zafirlukast inactive ingredients . zafirlukast contraindicated patients hepatic impairment including hepatic cirrhosis .",
    "ingredients": [
        {
            "name": "ZAFIRLUKAST",
            "code": "XZ629S5L50"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE, UNSPECIFIED FORM",
            "code": "J2B2A4N98G"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "organization": "Bryant Ranch Prepack",
    "name": "Zafirlukast",
    "effectiveTime": "20240628",
    "indications_original": "Zafirlukast is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older.",
    "contraindications_original": "Because food can reduce the bioavailability of zafirlukast, zafirlukast should be taken at least 1 hour before or 2 hours after meals.\n                  \n                     Adults and Children 12 years of age and older\n                  \n                  The recommended dose of zafirlukast in adults and children 12 years and older is 20 mg twice daily.\n                  \n                     Pediatric Patients 5 through 11 years of age \n                  \n                  The recommended dose of zafirlukast in children 5 through 11 years of age is 10 mg twice daily.\n                  \n                     Elderly Patients\n                  \n                  Based on cross-study comparisons, the clearance of zafirlukast is reduced in elderly patients (65 years of age and older), such that Cmax and AUC are approximately twice those of younger adults.  In clinical trials, a dose of 20 mg twice daily was not associated with an increase in the overall incidence of adverse events or withdrawals because of adverse events in elderly patients.\n                  \n                     Patients with Hepatic Impairment\n                  \n                  Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis (see CONTRAINDICATIONS). The clearance of zafirlukast is reduced in patients with stable alcoholic cirrhosis such that the Cmax and AUC are approximately 50 to  60% greater than those of normal adults.  Zafirlukast has not been evaluated in patients with hepatitis or in long-term studies of patients with cirrhosis.\n                  \n                     Patients with Renal Impairment\n                  \n                  Dosage adjustment is not required for patients with renal impairment.",
    "warningsAndPrecautions_original": "Zafirlukast 20 mg Tablets - white, round, biconvex, film-coated tablets debossed with \"P\" on one side and \"20\" on the other.\n                  NDC: 72162-2362-6: 60 Tablets in a BOTTLE\n                  Store at controlled room temperature, 20 to 25°C (68 to 77°F) [see USP]. Protect from light and moisture. Dispense in the original air-tight container.\n                  Repackaged/Relabeled by:Bryant Ranch Prepack, Inc.Burbank, CA 91504",
    "adverseReactions_original": "Zafirlukast is contraindicated in patients who are hypersensitive to zafirlukast or any of its inactive ingredients.\n                  Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis."
}